Cargando…
Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study
BACKGROUND: Information is scarce about biological disease-modifying antirheumatic drug (DMARD) switching patterns in children and young people (aged ≤16 years) with juvenile idiopathic arthritis in an era of many biologic therapies. The best choice of biologic to use if the first biological DMARD i...
Autores principales: | Kearsley-Fleet, Lianne, Heaf, Eleanor, Davies, Rebecca, Baildam, Eileen, Beresford, Michael W, Foster, Helen E, Southwood, Taunton R, Thomson, Wendy, Hyrich, Kimme L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134528/ https://www.ncbi.nlm.nih.gov/pubmed/32280951 http://dx.doi.org/10.1016/S2665-9913(20)30025-4 |
Ejemplares similares
-
Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016) -
Factors associated with choice of first biologic among children with juvenile idiopathic arthritis: a combined analysis from two UK paediatric biologic registers
por: Davies, Rebecca, et al.
Publicado: (2014) -
Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019) -
Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2022) -
Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)